share_log

EF Hutton Maintains Buy on Trxade Health, Lowers Price Target to $1.25

Benzinga ·  May 17, 2023 00:28

EF Hutton analyst Constantine Davides maintains Trxade Health (NASDAQ:MEDS) with a Buy and lowers the price target from $1.7 to $1.25.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment